ArticleBiosafety and health2025
Targeting anti-virulence factor strategies of bacterial pathogens.
Article in Biosafety and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Immunoinformatics-driven multi-epitope vaccine design as a promising strategy against multidrug-resistant pathogens: a comprehensive review.Folia microbiologica · 2026Review
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Repurposing Tirazone as an effective quorum-sensing inhibitor against Pseudomonas aeruginosa virulence and biofilm formation.The Journal of antibiotics · 2026Article
- Beyond antibiotics: Multidimensional interventions and coordinated governance against ESKAPE resistance.Biosafety and health · 2026Article
- Organosulfur scaffolds as quorum sensing and biofilm modulators in Gram-negative bacteria.FEMS microbiology reviews · 2026Review
- Modulation ofInfection and drug resistance · 2026Article
- Binding ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Anti-QS Strategies AgainstMicroorganisms · 2025Review
- Carbapenem-resistant hypervirulent Klebsiella pneumoniae: where is it headed in the tug-of-war between virulence and resistance?EBioMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-resistant bacterial pathogens pose substantial biosafety and health hazards, leading to millions of deaths each year. The evolution of bacterial virulence factors is mainly propelled by horizontal gene transfer (HGT). In addition to traditional antibiotics, antimicrobial strategies targeting biofilm-related virulence factors and quorum sensing (QS)-related virulence factors can effectively restrain drug-resistant bacteria. Future anti-virulence strategies, encompassing natural drugs, antibiotic resistance inhibitors, monoclonal antibodies (mAbs), and vaccines, are in the development pipeline. Consequently, by disrupting virulence factors, these drugs can eliminate the ability of bacterial pathogens to cause disease. In conclusion, this Perspective comprehensively summarizes current anti-bacterial virulence factor strategies and prospects for future cutting-edge approaches, which may address the issues of antibacterial resistance and curtail the spread of pathogens in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.